Diversis Capital,, a Los Angeles-based private equity firm focused on acquiring and growing small- and middle-market companies, has acquired the majority of the assets of Caligor Rx, Inc.
Based in Secaucus, New Jersey with an additional facility in Dartford, UK, Caligor provides services that enable pharmaceutical and biotechnology companies to maximize the value of their clinical supply chain investments. Financial terms of the transaction were not disclosed.
From its roots as a pharmacy started in 1919, Caligor has established itself as a leader in sourcing and distributing comparator drugs for clinical trials worldwide. Complementing its comparator business, Caligor provides regulatory expertise and strategic services for setting up Global Access Programs (GAP). These programs supply investigational medicines to individual patients, and groups of patients, who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives. Caligor’s leadership team has implemented and managed these programs in more than 70 countries.
“Caligor has a strong, successful track record of delivering strategic clinical trial supply and logistics services to the pharmaceutical and biotechnology industries,” said Kevin Ma, a managing director for Diversis Capital. “We are excited about driving the next stage of Caligor’s growth and shaping its long-term strategy. We will provide additional resources and operational expertise to expand the Company’s comparator and GAP offerings, broaden the reach of its businesses to new geographic regions, enhance its logistics capabilities and build on its leadership position.”
Diversis plans to invest heavily in Caligor to enhance its sales and marketing, logistics capabilities, distribution infrastructure and service offerings. These investments will include a new warehouse in Dartford, UK. Slated to open in late 2016, the warehouse will have about five times more space than the current UK facility.
“We are excited about the opportunity to provide Caligor’s current and future clients with an enhanced array of services to further optimize their clinical programs and bring new drugs to market more efficiently,” says Ron Nayot, a managing director for Diversis Capital.
Tammy Bishop, previously managing director of Caligor, becomes CEO of the Company. “Our entire global team is delighted to become part of the Diversis portfolio,” she says. “This acquisition underscores a strong belief in Caligor’s long-term growth. Diversis’ commitment to invest significant resources in Caligor – in our people, systems and capabilities – ultimately benefits clients as well as employees."
